Skip to main content
. Author manuscript; available in PMC: 2014 Sep 2.
Published in final edited form as: Arthritis Care Res (Hoboken). 2014 Jun;66(6):897–906. doi: 10.1002/acr.22233

Table 3.

Time trends in medical comorbidity from 1993 to 2005 in patients undergoing primary TKA

1993–1995 1996–1998 1999–2001 2002–2005 P-value
Deyo-Charlson comorbidities (in %)
 Myocardial Infarction 4.2 4.6 4.9 5.8 0.10
 Congestive Heart Failure 2.7 2.9 5.5 4.8 <0.001
 Peripheral Vascular Disease 3.9 3.5 5.5 7.7 <0.001
 Cerebrovascular disease 6.1 6.2 8.0 9.5 <0.001
 Dementia 0.1 0.2 0.3 0.2 0.65
 COPD 8.5 8.1 12.0 13.3 <0.001
 Peptic ulcer disease 7.2 7.1 8.9 10.3 <0.001
 Mild liver disease 1.3 1.6 2.3 3.0 0.001
 Diabetes 6.8 9.8 10.4 12.2 <0.001
 Diabetes with end organ damage 1.1 2.4 2.8 3.9 <0.001
 Hemiplegia 0 0.2 0.4 0.4 0.04
 Moderate/severe renal disease 3.8 4.3 5.3 7.9 <0.001
 Moderate/severe liver disease 0.1 0.4 0.5 0.8 0.02
 Metastatic solid tumor 4.0 2.8 2.6 3.1 0.09
 AIDS 0.1 0 0 0 0.29
 Rheumatologic disease 9.8 7.0 8.5 6.2 <0.001
 Other cancer 12.8 12.3 14.1 17.6 <0.001
Mean Deyo-Charlson Score (SD) 1.1 (1.9) 1.1 (1.9) 1.3 (2.0) 1.5 (2.2) <0.001

COPD, Chronic Obstructive Pulmonary Disease; AIDS, Acquired Immune Deficiency Disease; SD, standard deviation